Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Dextromethorphan Stories

2013-08-06 16:28:13

ALISO VIEJO, Calif., Aug. 6, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and nine-months ended June 30, 2013. (Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO) Quarterly Financial Highlights Total company net revenues of $19.8 million Gross and net NUEDEXTA® sales increased to $24.3 million and $19.0 million, respectively, representing growth of 17% and 15% versus the previous quarter Cash, cash...

2013-07-01 08:27:40

ALISO VIEJO, Calif., July 1, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced completion of patient enrollment in the company's phase II, placebo controlled study testing three doses of AVP-923 for the treatment of central neuropathic pain in multiple sclerosis. Top-line results from this study are expected in the fourth calendar quarter of 2013. (Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO) "Final completion of enrollment in...

2013-06-25 12:30:22

ALISO VIEJO, Calif., June 25, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the European Commission has approved NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) in the European Union for the treatment of pseudobulbar affect (PBA), irrespective of underlying neurologic disease or injury. (Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO) "The approval of NUEDEXTA by the European Commission is a major breakthrough for...

2013-06-05 08:28:55

Expedited Development Path will Allow Seamless Integration of AVP-786 into ongoing Clinical Programs ALISO VIEJO, Calif., June 5, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. Food and Drug Administration (FDA) has agreed to an expedited development pathway for their next-generation compound, AVP-786, requiring only a limited pre-clinical package as part of the Investigational New Drug (IND) application. Upon completion of these...

2013-04-26 08:24:11

NUEDEXTA recommended for the treatment of PBA, irrespective of neurologic cause ALISO VIEJO, Calif., April 26, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for NUEDEXTA(®) (dextromethorphan hydrobromide and quinidine sulfate), recommending NUEDEXTA be approved for the treatment of pseudobulbar affect (PBA),...

2013-02-11 08:24:54

EL PASO, Texas, Feb. 11, 2013 /PRNewswire-iReach/ -- While many consumers have become aware of the potential risk of abuse when it comes to taking prescription medications, a recent article from The Philadelphia Inquirer reveals that many teenagers are finding ways to use a wide array of over-the-counter medication recreationally. Despite the fact that these products are easily accessible and do not require a prescription to purchase, the side effects have proven severe and in some cases,...

2013-02-07 08:27:47

ALISO VIEJO, Calif., Feb. 7, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) announced today that it has successfully completed the first of a two-stage pharmacokinetic study with AVP-786, a drug product containing a deuterium modified form of dextromethorphan. Based on interim data, Avanir believes that it has identified a formulation of AVP-786 with a comparable pharmacokinetic, safety and tolerability profile to AVP-923 (dextromethorphan hydrobromide and quinidine...

2013-01-31 16:26:09

OTTAWA, Jan. 31, 2013 /CNW/ - Health Canada is advising Canadians that Novartis Consumer Health Canada Inc. is conducting a voluntary recall of 17 products (see chart below) as the child resistant mechanism of the bottle cap can fail. As a result, children may be able to open the bottle and ingest the product. The ingredients of the affected products may be harmful to children and as such, ingestion of these products may cause serious adverse health consequences, including death....

2012-12-12 16:25:09

ALISO VIEJO, Calif., Dec. 12, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and twelve months ended September 30, 2012. Quarterly Financial Highlights Gross and net NUEDEXTA® sales of $15.4 million and $12.4 million, respectively, an increase of 26% and 23% versus the previous quarter Total company net revenue of $13.5 million Cash, cash equivalents, and restricted investments of $72.1 million as of September 30,...

2012-11-27 08:28:54

ALISO VIEJO, Calif., Nov. 27, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced preliminary results for the quarter ended September 30, 2012. Financial Update Based on preliminary results for the fourth fiscal quarter ended September 30, 2012, Avanir estimates: Gross revenue for NUEDEXTA® of $15.4 million, representing an increase of approximately 26% over the prior quarter Total operating expenses, excluding cost of product sales and non-cash...